Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19245942 | 0.91 | BRD4 (0.39) | PDE3BPDE3ABRD4GAAALDH1A1 | |
| SCHEMBL17967309 | 0.88 | PDE3B (0.33) | PDE3BPDE3APDE1APDE1BPDE1C | |
| SCHEMBL15913967 | 0.88 | RAB9A (0.39) | BRD4GAAALDH1A1NR4A2KDM4E | |
| SCHEMBL15064604 | 0.78 | BRD4 (0.38) | BRD4GAAALDH1A1NR4A2KDM4E | |
| SCHEMBL16447915 | 0.77 | BRD4 (0.37) | BRD4GAAALDH1A1NR4A2KDM4E | |
| SCHEMBL18567026 | 0.77 | HTT (0.35) | PDE3BPDE3ABRD4GAAALDH1A1 | |
| SCHEMBL19755582 | 0.77 | BRD4 (0.37) | BRD4GAAALDH1A1NR4A2KDM4E | |
| SCHEMBL19041068 | 0.76 | HTT (0.36) | PDE3BPDE3ABRD4GAAALDH1A1 | |
| SCHEMBL2415069 | 0.76 | KDM4E (0.38) | BRD4GAAALDH1A1NR4A2KDM4E | |
| SCHEMBL19158138 | 0.76 | PLA2G4A (0.38) | BRD4GAAALDH1A1NR4A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20180215769-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9732092-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9663528-B2 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | ZC3HAV1, PYM1, CCR5 | PDE3B 882/4885PDE3A 671/4885PDE1A 4269/4885 |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | PYM1, ZYX, XDH | PDE3B 1036/4885PDE3A 867/4885PDE1A 4599/4885 |
| US-20180215769-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, ZYX, ZC3HAV1L | PDE3B 1764/4885PDE3A 1521/4885PDE1A 3061/4885 |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | PYM1, ZC3HAV1, CD4 | PDE3B 1301/4885PDE3A 1031/4885PDE1A 4286/4885 |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PDE3B 1700/4885PDE3A 1482/4885PDE1A 3124/4885 |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | PDE3B 1700/4885PDE3A 1482/4885PDE1A 3124/4885 |
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | PYM1, XDH, CYP2S1 | PDE3B 1253/4885PDE3A 1147/4885PDE1A 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.